A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers
Status:
Not yet recruiting
Trial end date:
2026-01-21
Target enrollment:
Participant gender:
Summary
Insulin icodec is a new medicine which is under development for use in humans and is not yet
available at the pharmacy. It is being developed for the treatment of diabetes, a condition
that causes high blood sugar levels. Insulin icodec will be investigated in participants with
type 2 diabetes. Participant will get one dose of insulin icodec, which will be administered
in the afternoon or evening of the day of dosing. The study will last for about 8 weeks.
Insulin icodec will be injected into a skin fold with a small needle (subcutaneous
application) using a pen injector prefilled with a volume of 3 milliliter (mL) (a little less
than a quarter of a teaspoonful). The amount of insulin icodec participant will receive
depends on participant's body weight. Participant must not participate if participant meets
certain conditions called exclusion criteria, such as an age of above 18 years when the
informed consent is signed or has serious health conditions. Female participant cannot take
part if she is pregnant, breast-feeding or planning to become pregnant during the study
period.